Is Higher Adherence Required for Women Using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis?
- PMID: 37586099
- DOI: 10.1093/cid/ciad485
Is Higher Adherence Required for Women Using Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis?
Conflict of interest statement
Potential conflicts of interest. P. K. D. reports receiving research funding, paid to his institution, from the US National Institutes of Health, US Centers for Disease Control and Prevention, Bill and Melinda Gates Foundation, Abbott Laboratories, and InBios International; scientific advisory board (SAB) and/or consulting fees from ThermoFisher, Abbvie, Cepheid, InBios International, Abbott Diagnostics, PATH, LumiraDx, OraSure, Oxford Immunotec, Alveo Technologies, and Quidel. X. N. reports no potential conflicts. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment in
-
Reply to Niu and Drain.Clin Infect Dis. 2024 Mar 20;78(3):802-803. doi: 10.1093/cid/ciad486. Clin Infect Dis. 2024. PMID: 37586097 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
